For Kidney Patients, No One Size-Fits-All Treatment For Coronary Artery Disease

MedicalResearch.com Interview with:
Sripal Bangalore, MD, MHA, FACC, FAHA, FSCAI, Director of Research, Cardiac Catheterization Laboratory, Director, Cardiovascular Outcomes Group, The Leon H. Charney Division of Cardiology, Associate Professor of Medicine, New York University School of Medicine, New York, NY 10016.Dr.Sripal Bangalore MD, MHA, FACC, FAHA, FSCAI,
Director of Research, Cardiac Catheterization Laboratory,
Director, Cardiovascular Outcomes Group,
Associate Professor of Medicine,
New York University School of Medicine,
New York, NY 10016,
Principal Investigator ISCHEMIA-CKD trial

 Medical Research: What is the background for this study? What are the main findings?

Dr. Bangalore: Patients with chronic kidney disease are at high risk of coronary artery disease. However, they are also at risk for worsening kidney function from revascularization procedures and have been routinely excluded from clinical trials of stenting vs bypass surgery. In this registry study of over 5900 patients with multivessel coronary artery disease who underwent bypass surgery or stenting using the latest generation drug eluting stent (everolimus eluting stent), we showed that there are trade off between both procedures. With bypass surgery there was increase in the risk of death, myocardial infarction and stroke in the short term (in-hospital/30-days). For PCI, there was long term risk of repeat revascularization and also increase in myocardial infarction in those who achieved incomplete revascularization.

Medical Research: What should clinicians and patients take away from your report?

Dr. Bangalore: For patients with chronic kidney disease and multivessel coronary artery disease, there is no one size fits all approach for treatment of coronary artery disease. Clinicians and patients should weigh the short term risks of CABG with long term risk of PCI.

Medical Research: What recommendations do you have for future research as a result of this study?

Dr. Bangalore: Clinical trials are needed to figure out which of the two procedures are optimal for patients with chronic kidney disease.

Citation:

Bangalore S, Breazna A, DeMicco DA, Wun C, Messerli FH. Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes: Insights From the TNT Trial. J Am Coll Cardiol. 2015;65(15):1539-1548. doi:10.1016/j.jacc.2015.02.017.

[wysija_form id=”5″]

MedicalResearch.com is not a forum for the exchange of personal medical information, advice or the promotion of self-destructive behavior (e.g., eating disorders, suicide). While you may freely discuss your troubles, you should not look to the Website for information or advice on such topics. Instead, we recommend that you talk in person with a trusted medical professional.

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
MedicalResearch.com Interview with:Sripal Bangalore, MD, MHA (2015). For Kidney Patients, No One Size-Fits-All Treatment For Coronary Artery Disease 

Last Updated on September 8, 2015 by Marie Benz MD FAAD